Comparative Analysis of National Drug Policies - Second Workshop Geneva, 10-13 June 1996 - EDM Research Series No. 025
(1997; 175 pages) View the PDF document
Table of Contents
View the documentExecutive summary
View the documentI. Introduction
Open this folder and view contentsII. Background on the research project
Open this folder and view contentsIII. Second workshop
Open this folder and view contentsIV. Preliminary findings
Open this folder and view contentsV. Conclusions of the workshop and follow-up plans
Open this folder and view contentsAnnex 1: Research proposal
View the documentAnnex 2: List of participants
View the documentAnnex 3: Agenda
View the documentAnnex 4: Questionnaire on NDP performance assessment
Close this folderAnnex 5: Achievements of the national drug policies in the 12 countries
View the documentBulgaria
View the documentChad
View the documentColombia
View the documentGuinea
View the documentIndia
View the documentMali
View the documentPhilippines
View the documentSri Lanka
View the documentThailand
View the documentViet Nam
View the documentZambia
View the documentZimbabwe
View the documentAnnex 6: Consolidated tables
View the documentOther documents in the DAP Research Series

Annex 5: Achievements of the national drug policies in the 12 countries

This annex contains a one-page table for each country which used the NDP indicators for assessing its national drug policy, namely Bulgaria, Chad, Colombia, Guinea, India, Mali, Philippines, Sri Lanka, Thailand, Viet Nam, Zambia and Zimbabwe.

Each page contains rated information on:

1. The achievement of the NDP in relation to the four objectives: availability of essential drugs, accessibility of essential drugs, quality of drugs, rational use of drugs.

2. The level of implementation of each key component of the NDP: legislation and regulation, essential drugs selection and drug registration, drug allocation in the health budget/public sector financing policy, public sector procurement procedures, public sector distribution and logistics, pricing policy, information and continuing education on drug use (structure and process).

The rating was done by the teams during the workshop on the basis of the data collected in each country. It used both calculation of averages and judgment related to the relative importance of the various indicators in each subgroup. It was refined later in DAP once new and more accurate data were sent by the countries (see Annex 6).

It should however be seen as tentative and is provided in this annex as an example of what can be achieved with the results of an indicator exercise

to previous section
to next section
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: December 6, 2017